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Clinical Infectious Diseases
SUPPLEMENT ARTICLE

Is Higher Viral Load in the Upper Respiratory Tract
Associated With Severe Pneumonia? Findings From the
PERCH Study
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Background. The etiologic inference of identifying a pathogen in the upper respiratory tract (URT) of children with pneumonia
is unclear. To determine if viral load could provide evidence of causality of pneumonia, we compared viral load in the URT of children with World Health Organization–defined severe and very severe pneumonia and age-matched community controls.
Methods. In the 9 developing country sites, nasopharyngeal/oropharyngeal swabs from children with and without pneumonia
were tested using quantitative real-time polymerase chain reaction for 17 viruses. The association of viral load with case status was
evaluated using logistic regression. Receiver operating characteristic (ROC) curves were constructed to determine optimal discriminatory viral load cutoffs. Viral load density distributions were plotted.
Results. The mean viral load was higher in cases than controls for 7 viruses. However, there was substantial overlap in viral load
distribution of cases and controls for all viruses. ROC curves to determine the optimal viral load cutoff produced an area under the
curve of <0.80 for all viruses, suggesting poor to fair discrimination between cases and controls. Fatal and very severe pneumonia
cases did not have higher viral load than less severe cases for most viruses.
Conclusions. Although we found higher viral loads among pneumonia cases than controls for some viruses, the utility in using viral
load of URT specimens to define viral pneumonia was equivocal. Our analysis was limited by lack of a gold standard for viral pneumonia.
Keywords. pneumonia; viral load; viral density; RSV; PERCH.

For diagnosing viral pneumonia, upper respiratory tract (URT)
specimens have become the most common specimen type due
a
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to their logistical ease of collection [1, 2]. However, detection
of viruses in URT specimens has low specificity as this finding
might simply reflect an URT infection without lower respiratory tract involvement or coincidental asymptomatic or past
infection [2–4].
A possible solution to the lack of specificity of simply detecting the presence or absence of a virus in the URT of pneumonia patients is to determine whether the density of a virus in
the URT can better distinguish its causative role in pneumonia. There are reports that a higher pathogen load in the URT is
associated with pneumonia, for both Streptococcus pneumoniae
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and some respiratory viruses [5–8]. In addition, for some
viruses, higher viral load in the URT has been associated with
worse outcomes [7, 9–11].
In this analysis, we describe viral load in nasopharyngeal/
oropharyngeal (NP/OP) specimens from cases and community
controls from a large multicountry childhood pneumonia study
(Pneumonia Etiology Research for Child Health [PERCH]), as
well as demographic and clinical characteristics associated with
higher viral load and disease severity. An overarching aim was
to explore whether the incorporation of viral load data into the
main PERCH etiology analysis might improve the assignment
of the etiology of pneumonia cases.
METHODS

The PERCH study design and enrollment strategy has been
previously described [12]. In brief, PERCH is a case-control
study of the etiology of World Health Organization (WHO)–
defined severe and very severe pneumonia among hospitalized children aged 1–59 months and age frequency-matched
community controls. Enrollment took place during August
2011–January 2014 for 24 months at each of 9 study sites
located in 7 countries—Dhaka and Matlab, Bangladesh;
Basse, The Gambia; Kilifi, Kenya; Bamako, Mali; Soweto,
South Africa; Nakhon Phanom and Sa Kaeo, Thailand; and
Lusaka, Zambia [13].
Case and Control Definitions

For this analysis, we included only cases with evidence of
pneumonia on chest radiograph, defined as consolidation
and/or any other infiltrate assessed according to the WHO
radiological pneumonia criteria [14]. A control participant
was considered to have a respiratory tract illness (RTI) if
cough or runny nose was reported. RTI was also considered
present if a child had (1) at least 1 of ear discharge, wheezing,
or difficulty breathing and (2) either a measured temperature
of ≥38.0°C within the previous 48 hours or a history of sore
throat. Controls who did not meet the definition of RTI are
referred to as non-RTI controls.
Specimen Collection and Laboratory Testing

Nasopharyngeal and oropharyngeal swabs were collected from
PERCH cases and controls at enrollment. Nasopharyngeal
specimens were collected by inserting flocked swabs (Copan
ETC) into the posterior nasopharynx and rotating 180° for 2–3
seconds. Oropharyngeal specimens were then collected by rubbing Rayon swabs (Fisher Scientific) over both tonsillar pillars
and the posterior oropharynx for several seconds. Following
collection, swabs were placed together in the same 3-mL vial
of universal transport media (Copan) and processed within 24
hours of collection. Specimens were left at room temperature
for no more than 2 hours or at 4°C for no more than 24 hours,
before freezing at –70°C.
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All specimens were tested in-country using a standardized methodology, and details are described elsewhere [15].
Specimens were evaluated using the Fast-track Diagnostics
Respiratory Pathogens 33 test (FTD Resp 33, Fast-track
Diagnostics, Sliema, Malta), a 33-target, 8-multiplex real-time
polymerase chain reaction (PCR) platform for the detection
of viruses, bacteria, and fungi. The 18 viruses or virus classes
included influenza A, B, and C viruses; parainfluenza virus
(PIV) types 1, 2, 3, and 4; coronaviruses NL63, 229E, OC43,
and HKU1; human metapneumovirus (HMPV) A and B (A
and B not differentiated); rhinovirus; respiratory syncytial
virus (RSV) A and B (A and B not differentiated); adenovirus;
enterovirus and parechovirus (not differentiated); human bocavirus (HBOV); and cytomegalovirus. Cytomegalovirus is not
included in this analysis but is discussed in a separate publication of the pathogen load of pathogens commonly detected in
both cases and controls [16].
Some sites (Bangladesh, The Gambia, Mali, South Africa)
collected lung aspirates from children with consolidation on
chest radiograph who met clinical and radiologic criteria for the
Table 1. Characteristics of Chest Radiograph–Positive Children With
Severe and Very Severe Pneumonia and Controls—Pneumonia Etiology
Research for Child Health (PERCH) Study, August 2011–January 2014

Characteristic

CXR+Casesa
(n = 1733)

All Controls
(n = 4986)

χ2 P Valueb

Site
Kenya

282 (16.3)

855 (17.2)

The Gambia

273 (15.8)

624 (12.5)

Mali

239 (13.8)

724 (14.5)

Zambia

189 (10.9)

535 (10.7)

South Africa

433 (25.0)

823 (16.5)

98 (5.7)

657 (13.2)

219 (12.6)

768 (15.4)

1–5 mo

680 (39.2)

1555 (31.2)

6–11 mo

415 (24.0)

1187 (23.8)

12–23 mo

424 (24.5)

1235 (24.8)

24–59 mo

214 (12.4)

1009 (20.2)

Female sex

756 (43.6)

2477 (49.7)

<.001

Prior antibiotic usec

597 (42.4)

84 (1.7)

<.001

NA

1185 (23.8)

NA

Thailand
Bangladesh

<.001

Age

Respiratory tract
illnessd

<.001

No. of viruses detected
0 viruses

180 (10.4)

1048 (21.0)

1 virus

628 (36.2)

1928 (38.7)

2 viruses

616 (35.6)

1420 (28.5)

≥3 viruses

309 (17.8)

590 (11.8)

<.001

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CXR+, chest radiograph positive; NA, not applicable.
a

CXR+ defined as having radiographic evidence of pneumonia.

b

Comparing distribution of characteristics between CXR+ cases and controls. Bolded values are significant (P < .05).

c

Prior antibiotic use: administered antibiotics at the study facility prior to the collection
of specimens (cases only), antibiotics at a referral facility (cases only), or positive serum
bioassay (cases and controls).
d

See Methods for respiratory tract illness definition.

procedure [17]. Lung aspirate specimens were tested for viral
targets using the same method described for NP/OP specimens.
Statistical Analysis

Human immunodeficiency virus (HIV)–positive cases were
excluded from analyses unless stated otherwise. PCR quantification was log10-transformed. Demographic characteristics of cases and controls were compared using the χ2 test. All
controls, both RTI and non-RTI, were included in the main
analysis. All analyses of viral load were restricted to children
positive for each virus. Among children positive for each virus,
t tests adjusted for site and age were performed to compare
mean cycle threshold (Ct) values between cases and controls.
For each virus, a trend analysis, using simple linear regression,
was performed to test if viral density increased with age for
cases and for controls. Among cases only, mean Ct values were
also compared by days since onset, severity, vital status, and
HIV status. Multivariable logistic regression, adjusting for age
and site, was performed to compare odds of being a case for
each 3.4-unit drop in Ct value, which was approximately equivalent to a 1 log10 increase in viral copies/mL; Ct values instead
of viral density were used for regression because viral density
was only accurate within the linear range of the assay (104–108
copies/mL). Kernel density distribution plots were created

to show distributions of viral density by case/control status.
Receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC) were generated to investigate the performance of viral load in determining case status
among children positive by NP/OP PCR for each virus, and the
Youden index was calculated to determine the optimized diagnostic cutoffs to differentiate cases and controls [18]. To guard
against bias in the estimates of sensitivity due to having a small
number of some viruses detected among cases, the Youden
index was calculated using leave-one-out cross-validation
where sample size was sufficient [19]. Redefining positivity
using the optimal cutpoints, we calculated odds ratios associated with case status for children above vs below the optimal
cutpoint including negatives. The proportion of radiographically confirmed cases attributable to each virus [population
attributable fraction: population prevalence × (1 – 1 / OR)] was
calculated using 2 methods: (1) any positive vs negative and
(2) positive above vs below the optimal cutpoint, the former
method being optimal for laboratory sensitivity and the latter
for a balance of epidemiological sensitivity and specificity. All
analyses were performed using SAS software version 9.4 (SAS
Institute, Cary North Carolina) and R Statistical Software 3.2.1
(R Foundation for Statistical Computing, Vienna, Austria). All
P values are 2 sided.

Table 2. Mean Nasopharyngeal/Oropharyngeal Polymerase Chain Reaction Cycle Threshold Values for Chest Radiograph–Positive Cases and Controls
and Odds Ratios for Viral Load Being Predictive of Case Status—Pneumonia Etiology Research for Child Health (PERCH) Study, August 2011–January 2014
CXR+ Casesa (n = 1733)

Virus

No.b

(%)b

Adenovirus

All Controls (n = 4986)

Ct Value Meanc
(95% CI)

No.b

(%)b

Ct Value Meanc
(95% CI)

P Valued

OR per 1 Log10 Increase,
Copies/mL (95% CI)e

164

(9.5)

27.7 (26.8–28.5)

594

(11.9)

29.5 (29.2–29.8)

<.001

Coronavirus 229

18

(1.1)

31.1 (28.6–33.5)

54

(1.1)

30.2 (28.3–32.0)

.58

Coronavirus 43

38

(2.2)

26.4 (24.4–28.5)

192

(3.9)

28.0 (27.1–28.8)

.30

1.13 (.91–1.39)

Coronavirus 63

36

(2.1)

27.0 (25.3–28.7)

158

(3.2)

28.5 (27.7–29.3)

.26

1.18 (.90–1.55)

Coronavirus HKU

37

(2.2)

29.2 (27.0–31.4)

111

(2.2)

27.7 (26.5–28.9)

.40

0.91 (.74–1.13)

Influenza A

62

(3.6)

28.5 (27.7–29.4)

57

(1.2)

29.8 (28.4–31.2)

.31

1.21 (.85–1.72)

Influenza B

18

(1.1)

27.6 (25.7–29.5)

29

(0.6)

28.5 (26.7–30.3)

.82

1.07 (.63–1.83)

Influenza C

10

(0.6)

28.1 (24.8–31.4)

29

(0.6)

27.3 (25.3–29.3)

.14

0.44 (.17–1.15)

HBOV

231

(13.4)

30.5 (29.6–31.3)

660

(13.3)

31.7 (31.3–32.1)

.007

1.13 (1.03–1.24)

HMPV A/B

185

(10.8)

28.1 (27.6–28.7)

206

(4.1)

28.9 (28.2–29.5)

.02

1.23 (1.03–1.46)

Parainfluenza 1

89

(5.2)

26.1 (24.9–27.2)

49

(1.0)

29.4 (27.6–31.2)

.008

1.37 (1.08–1.74)

Parainfluenza 2

23

(1.3)

34.0 (31.7–36.3)

53

(1.1)

35.1 (33.9–36.3)

.70

1.10 (.71–1.69)

Parainfluenza 3

104

(6.1)

25.0 (24.0–25.9)

142

(2.9)

29.0 (28.0–30.0)

<.001

1.47 (1.22–1.77)

Parainfluenza 4

1.27 (1.10–1.46)
0.89 (.62–1.26)

44

(2.6)

31.7 (30.3–33.1)

86

(1.7)

32.2 (31.3–33.1)

.88

PV/EV

131

(7.6)

30.1 (29.5–30.8)

423

(8.5)

30.4 (30.0–30.7)

.45

0.98 (.73–1.31)
1.08 (.89–1.31)

Rhinovirus

365

(21.2)

31.7 (31.3–32.0)

1056

(21.2)

32.4 (32.3–32.6)

.003

1.21 (1.08–1.35)

RSV

461

(26.8)

22.2 (21.8–22.5)

140

(2.8)

27.0 (26.1–28.0)

<.001

2.02 (1.71–2.37)

Abbreviations: CI, confidence interval; Ct, cycle threshold; CXR+, chest radiograph positive; HBOV, human bocavirus; HMPV, human metapneumovirus; OR, odds ratio; PV/EV, parechovirus/
enterovirus; RSV, respiratory syncytial virus.
a

CXR+ defined as having radiographic evidence of pneumonia.

b
c

No. (%) positive in the nasopharynx/oropharynx among those with available results for the given virus.

Among those with a positive density.

d

Comparing mean cycle threshold value of CXR+ cases vs all controls using linear regression adjusting for age and site. Bolded values are significant (P < .05).

e

Odds ratio is for approximately each 3.4-unit drop in Ct value (equivalent to approximately 1 log10 increase in copies/mL) adjusting for age and site using logistic regression. Bolded values
are significant (P < .05).
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Figure 1. Nasopharyngeal/oropharyngeal viral load (log10 copies/mL) for chest radiograph–positive (CXR+) cases and all controls among those in which the virus was
detected—Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. CXR+ defined as having radiographic evidence of pneumonia. Box-andwhiskers plot features include the following: central line in box is median, bottom line of box is first quartile (25%), top line of box is third quartile (75%), diamond is mean,
and top and bottom of whiskers represent 95% confidence intervals. Area above the upper dotted line and below the lower dotted line indicate areas outside the linear range
of the assay for calculation of viral load from cycle threshold (Ct) values where there is a greater degree of uncertainty in viral density calculations. Numbers on x-axis indicate
number of positive results for that virus. *P value comparing mean Ct value between controls and CXR+ cases <.05 after adjusting for age and site. Abbreviations: Adeno,
adenovirus; Boca, human bocavirus; CXR, chest radiograph; Flu, influenza virus; HCoV, human coronavirus; HMPV, human metapneumovirus; Para, parainfluenza virus; PV/EV,
parechovirus/enterovirus; Rhino, rhinovirus; RSV, respiratory syncytial virus.

Ethical Considerations

The PERCH study protocol was approved by the institutional
review board or ethical review committee at each of the study
site institutions and at the Johns Hopkins Bloomberg School of
Public Health. Parents or guardians of all participants provided
written informed consent.
RESULTS

Of 1935 radiographically confirmed cases and 5325 controls in
PERCH, 1733 cases (1227 severe, 506 very severe) and 4986 controls (1185 RTI and 3801 non-RTI) were not known to be HIV
infected and had viral density results available for analysis (Table 1).
Overall, 89.6% of cases and 79.0% of controls had at least
1 virus detected, and 53.4% and 40.3%, respectively, had ≥2
viruses detected (Table 1). Among the 17 viruses tested, RSV
was the most commonly detected among cases (27%) but was
uncommon among controls (3%) (Table 2). Rhinovirus was the
next most commonly detected virus in cases but was present at
a similar frequency among controls (21% for both).
Analysis of Viral Load Among Cases and Controls

RSV had the highest mean viral load among cases (7.3 log copies/mL; Figure 1); no viruses other than RSV had a mean viral
S340 • CID 2017:64 (Suppl 3) • Feikin et al

load >6 log copies/mL. Among controls, no viruses had a mean
viral load >6 log copies/mL. Eight viruses among cases (RSV,
influenza C, PIV1, PIV3, PIV4, coronavirus 43, coronavirus
63, and HMPV) had mean viral loads >5 log copies/mL vs 5
viruses among controls (RSV, influenza C, PIV4, coronavirus
43, and coronavirus 63). There were 7 viruses that had significantly higher mean viral density among cases after adjusting
for site and age—adenovirus, HBOV, HMPV, PIV1, PIV3, rhinovirus, and RSV. After adjusting for age and site, there was
a significant increase in the odds of being a case (vs a control) for each 3.4-unit drop in Ct value (approximately 1 log
increase in copies/mL) for the same 7 viruses, ranging from a
13% increased odds for HBOV to a 102% increased odds for
RSV (Table 2).
Viral load was similar between RTI and non-RTI controls for
most viruses with the exception of RSV, where the mean viral load
was significantly higher for RTI controls (Supplementary Figure 1).
Despite the differences in viral load between cases and controls noted above, there was substantial overlap in the viral density distribution between cases and controls in which virus was
detected, as shown in the box plots and kernel density distribution plots (Figures 1 and 2). Kernel density distribution plots
were examined for a bimodal distribution with a smaller subset

Figure 2. Kernel density distribution plots comparing nasopharyngeal/oropharyngeal (NP/OP) viral load among chest radiograph–positive (CXR+) cases and all controls for
each viral polymerase chain reaction (PCR) target—Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. Tick marks across the top of
each plot indicate viral load of each individual (first row of black ticks for cases and second row of gray ticks for controls). Dashed curves indicate areas outside the linear
range of the assay for calculation of viral load from cycle threshold values. Dotted dashed vertical lines indicate optimal cutpoint distinguishing cases and controls calculated
using Youden index. Black arrows in adenovirus and human metapneumovirus plots indicate NP/OP viral load of cases whose lung aspirate specimen was available and
PCR positive for that virus. Abbreviations: Adeno, adenovirus; Boca, human bocavirus; CXR, chest radiograph; Flu, influenza virus; HCoV, human coronavirus; HMPV, human
metapneumovirus; Para, parainfluenza virus; PV/EV, parechovirus/enterovirus; Rhino, rhinovirus; RSV, respiratory syncytial virus.
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of cases having viruses at a higher viral load that might be indicative of those with pneumonia due to that virus. Adenovirus,
coronavirus 229, and PIV1–3 had a suggestion of a bimodal distribution among cases. The NP/OP viral load for the 2 cases with
viruses detected in PCR of lung aspirates (ie, HMPV and adenovirus) fell within the distribution of viral loads for other cases, as
well as controls, positive for that virus (Figure 2).
When constructing ROC curves, no virus had an AUC >0.8
(Table 3). RSV had the highest AUC at 0.76, with only 3 other
viruses having an AUC between 0.6 and 0.7 (influenza A, PIV1,
and PIV3). Despite the low values for the AUC, when redefining
positive for a virus as those with viral loads above the ROC optimal
cutpoint value as determined by the Youden index, the odds ratio
for predicting case status increased substantially for some viruses,
approximately doubling for adenovirus, coronavirus 63, PIV2, and
RSV (Table 4). Although the odds ratios increased, the population
attributable fraction for most viruses did not change substantially,
or even decreased (eg, influenza A, RSV) due to the lower frequency of cases with densities above the optimal cutpoint (Figure
3). This is because while the odds ratios are higher at the higher
density cutoff, the prevalence of cases above the higher threshold
was lower, and thus the proportion of PERCH cases assigned to
the virus would not change appreciably by using the higher cutoff.

Table 3. Receiver Operating Characteristic Areas Under the Curve,
Optimal Nasopharyngeal/Oropharyngeal Polymerase Chain Reaction
Density Cutpoints for Determining Case Status, and Associated Positive
Rate in Cases and Negative Rate in Controls by Virus Among Chest
Radiograph–Positive Cases and Controls With Positive Densities—
Pneumonia Etiology Research for Child Health (PERCH) Study, August
2011–January 2014

Virusa

AUC

Optimal
Cutpointb,
(Log10 Copies/
mL)

Adenovirus

0.60

4.88

0.44

0.78

Coronavirus 43

0.57

6.94

0.36

0.74

Coronavirus 63

0.58

7.24

0.22

0.89

Influenza A

0.61

5.12

0.50

0.68

Influenza B

0.55

3.79

0.89

0.28

HBOV

0.54

5.81

0.20

0.89

HMPV A/B

0.54

3.9

0.91

0.20

Parainfluenza 1

0.65

4.62

0.75

0.55

Parainfluenza 2

0.54

5.64

0.26

0.91

Parainfluenza 3

0.69

4.75

0.81

0.54

PV/EV

0.53

4.38

0.40

0.71

Rhinovirus

0.56

3.64

0.55

0.56

RSV

0.76

6.30

0.84

0.59

Proportion of
CXR+c Cases
Above Cutpoint

Proportion of
Controls Below
Cutpoint

Abbreviations: AUC, area under the curve; CXR+, chest radiograph positive; HBOV, human
bocavirus; HMPV, human metapneumovirus; PV/EV, parechovirus/enterovirus; RSV, respiratory syncytial virus.
a

Viruses with adjusted odds ratios <1 (see Table 2) were excluded from table (coronavirus
229, coronavirus HKU, influenza C, and parainfluenza 4).
b
Calculated using Youden index and, where possible, leave-one-out cross-validation.
Leave-one-out cross-validation was not performed for influenza B, parainfluenza 2, or
parechovirus/enterovirus.
c

CXR+ defined as having radiographic evidence of pneumonia.
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Predictors of Viral Load

We explored several potential predictors of viral density
among cases. When NP/OP specimens were collected earlier
in the course of illness, mean viral load was higher for RSV,
PIV1, and PIV3 and was lower for adenovirus; no significant
difference was observed for the other viruses (Supplementary
Table 1). The viral load among cases did not vary by age for
most viruses, including RSV, but a significant trend toward
decreasing viral load with increasing age was observed for a
few viruses, including adenovirus and RSV, which was also
observed among controls (Supplementary Figure 2). A slight,
but significant trend toward increasing viral load with increasing age was seen for rhinovirus among cases, but a significant
trend in the opposite direction was observed for controls.
In general, viral load did not vary by study site. One notable
exception was higher PIV1 viral load in The Gambia site (the
only site with a PIV1 outbreak, data not shown). HIV-infected
cases had a higher mean viral load for coronavirus 43 and a
lower viral load for HMPV, PIV3, and RSV (Supplementary
Table 2). There were no significant differences in the viral load
between cases who were normally nourished vs malnourished
(except PIV1 viral load was higher in normally nourished,
data not shown).
We assessed whether viral load was associated with pneumonia severity. Rhinovirus was the only virus with higher mean
viral load for very severe pneumonia compared to severe pneumonia (Supplementary Figure 3). Influenza A was the only
virus with higher mean viral load in fatal compared with surviving cases (Supplementary Figure 4). Furthermore, we compared mean viral densities between cases with evidence of an
other infiltrate (without alveolar consolidation) on chest radiograph to cases with evidence of alveolar consolidation (without
evidence of an other infiltrate). No significant differences were
found for any virus after adjusting for site and age.

DISCUSSION

In the PERCH study, the evidence for the utility of NP/OP
viral load in distinguishing radiographically confirmed cases
of severe or very severe pneumonia from controls was mixed.
On the one hand, we found a higher mean viral load in NP/OP
samples from severe and very severe pneumonia cases than from
community controls without pneumonia for several respiratory
viruses. Moreover, for many viruses, using a higher viral load
threshold to define positivity that maximized the combination
of sensitivity and specificity increased the odds ratio for case status over a simple binary (presence/absence) definition of positivity based on viral detection, which has high sensitivity but low
specificity. On the other hand, there was substantial overlap in
the distribution of NP/OP viral load densities among cases and
controls, even for RSV, the virus most strongly associated with
case status. No cutoffs clearly distinguished cases from controls.

Table 4. Nasopharyngeal/Oropharyngeal Prevalence of Viruses in Chest Radiograph–Positive Cases and Controls, Defining Positive as Any Detection of
Virus and Detection of Virus Above an Optimal Viral Load Cutpoint as Determined by Receiver Operating Characteristic Curves; Odds of Determining Case
Status Using Both Definitions of Positive— Pneumonia Etiology Research for Child Health (PERCH) Study, August 2011–January 2014

Negative
Virusa

CXR+ Casesb

Controls

Weak Positivec
(Below Optimal Cutpoint)

Strong Positived
(Above Optimal Cutpoint)

CXR+ Casesb

Controls

CXR+ Casesb

Controls

AORe (95% CI)
Any Positive vs
Negativef

AORe (95% CI)
Strong Positive vs
Weak Positive/
Negativeg

Adenovirus

1556 (90.5)

4384 (88.0)

92 (5.3)

470 (9.4)

72 (4.2)

126 (2.5)

0.88 (.73–1.07)

1.74 (1.28–2.36)

Coronavirus 43

1681 (97.7)

4785 (96.1)

25 (1.5)

149 (3.0)

14 (0.8)

43 (0.9)

0.52 (.36–.74)

0.81 (.44–1.49)

Coronavirus 63

1684 (97.9)

4819 (96.8)

28 (1.6)

147 (3.0)

8 (0.5)

11 (0.2)

0.63 (.43–.91)

1.78 (.71–4.47)

Influenza A

1658 (96.4)

4920 (98.9)

31 (1.8)

41 (0.8)

31 (1.8)

16 (0.3)

3.11 (2.15–4.49)

5.32 (2.87–9.85)

Influenza B

1702 (99.0)

4948 (99.4)

HBOV

1488 (86.6)

4316 (86.7)

2 (0.1)
184 (10.7)

8 (0.2)

16 (0.9)

21 (0.4)

1.82 (1.00–3.32)

2.24 (1.15–4.36)

593 (11.9)

47 (2.7)

68 (1.4)

1.11 (.94–1.31)

2.02 (1.38–2.96)

HMPV A/B

1534 (89.2)

4771 (95.9)

16 (0.9)

47 (0.9)

169 (9.8)

159 (3.2)

2.59 (2.09–3.21)

3.02 (2.40–3.82)

Parainfluenza 1

1630 (94.8)

4928 (99.0)

23 (1.3)

27 (0.5)

66 (3.8)

22 (0.4)

5.19 (3.60–7.49)

8.09 (4.92–13.32)

Parainfluenza 2

1697 (98.7)

4927 (98.9)

18 (1.0)

48 (1.0)

5 (0.3)

5 (0.1)

Parainfluenza 3

1616 (94.0)

4838 (97.1)

21 (1.2)

78 (1.6)

83 (4.8)

64 (1.3)

303 (6.1)

1.2 (.73–1.97)
2.13 (1.63–2.77)

2.55 (.72–9.04)
3.52 (2.51–4.92)

PV/EV

1589 (92.4)

4555 (91.5)

79 (4.6)

52 (3.0)

122 (2.4)

0.91 (.74–1.12)

1.22 (.87–1.71)

Rhinovirus

1260 (73.3)

3675 (73.8)

211 (12.3)

743 (14.9)

249 (14.5)

559 (11.2)

0.94 (.82–1.07)

1.26 (1.07–1.48)

RSV

1259 (73.2)

4840 (97.2)

73 (4.2)

83 (1.7)

388 (22.6)

57 (1.1)

12.55 (10.24–15.38)

24.72 (18.52–33.01)

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CXR+, chest radiograph positive; HBOV, human bocavirus; HMPV, human metapneumovirus; PV/EV, parechovirus/enterovirus; RSV, respiratory syncytial virus.
a

Viruses with adjusted odds ratios <1 for association of density (log copies/mL) with case status excluded from table (coronavirus 229, coronavirus HKU, influenza C, and parainfluenza
virus 4 as noted in Table 2).
b
c

CXR+ defined as having radiographic evidence of pneumonia.

Weakly positive: positive density below optimal cutpoint determined by Youden index. See Table 3.

d

Strongly positive: density above optimal cutpoint determined by Youden index. See Table 3.

e

Odds ratios adjusted for site and age. Bolded values are significant (P < .05).

f

Any positive includes those below and above optimal cutoff.

g

Strong positives are compared with combined negatives and weak positives.

Previous studies have also shown that the median or mean
RSV concentration of NP/OP specimens among children is
higher in cases of severe illness than among a healthy or mildly
ill control population [7–10, 20, 21]. However, few of these
studies compared the distribution of viral loads between severe

cases and controls. Those that did compare these 2 groups
showed an overlapping distribution similar to our study [8, 22].
Some studies of RSV viral load failed to show an association
with severe lower respiratory tract infection [23, 24], but these
studies included older children and adolescents in whom the

Figure 3. Adjusted population attributable fraction (PAF) for chest radiograph–positive cases using 2 methods: any positive vs negative (AF1) and positive above optimal
cutpoint vs positive below optimal cutpoint and negative (AF2)— Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. PAF = population
prevalence × (1 – 1 / odds ratio). Odds ratio (OR) is adjusted for other viruses, site, and age. Confidence intervals calculated using bootstrapping method. PAF not shown
where adjusted OR was <1 resulting in negative PAF. Abbreviations: Adeno, adenovirus; AF, attributable fraction; Boca, human bocavirus; Flu, influenza virus; HCoV, human
coronavirus; HMPV, human metapneumovirus; Para, parainfluenza virus; PV/EV, parechovirus/enterovirus.
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pathogenic significance of detecting RSV in the NP/OP is less
clear. One study of RSV viral load in infants showed no association with severe bronchiolitis [25] while another suggested that
viral load only influences clinical severity for first RSV infections in young infants [10].
In some studies, influenza viral load was associated with
severe disease [4, 26–29], while in others there was no association [8, 23, 27, 30–32]. A few studies have shown a higher viral
load in severe cases for HMPV [24, 33, 34]. Higher viral loads of
HBOV in nasopharyngeal aspirates were associated with greater
severity of illness among Chinese children [35]. Rhinovirus
viral load has been associated with more severe illness [22], but
not in some studies [8, 21]. Again, the majority of these studies
looked only at the central tendency of the viral load and did not
demonstrate a clear dichotomy in the distribution of viral loads
based on case status or severity category.
We did not find a higher viral load associated with greater
severity among pneumonia cases for most viruses. Cases who
died had a similar viral load as those who survived, and those
with very severe pneumonia had similar viral loads to those
children with severe pneumonia. This is in contrast with some
other studies of viruses in which higher viral load was observed
among RSV-infected children requiring mechanical ventilation
[9], and severe acute respiratory syndrome coronavirus– and
Middle East respiratory syndrome coronavirus–infected adults
who died [36, 37].
We undertook this analysis, in part, to determine if viral
loads of NP/OP specimens could be incorporated into the
PERCH analysis to identify etiologies of severe/very severe
pneumonia. Using a higher density threshold also did not have
an appreciable effect on the population attributable fraction for
most viruses, suggesting that using higher thresholds to assign
viral etiology to cases would likely have little impact on the
analysis of the etiologic distribution among the population of
PERCH cases [38]. In the final PERCH analyses, we will be able
to run sensitivity analyses to assess the impact of incorporating
viral density thresholds on the assessment of etiology.
In contrast to the accompanying analyses of bacterial pneumonia, our conclusions about the interpretation of viral load
and whether to include it in the main PERCH etiology analysis
were limited by the lack of a gold standard to diagnose viral
pneumonia [5, 16]. There were few PERCH cases who underwent lung aspirate procedures and even fewer who had a lung
aspirate in which a virus was detected in their lungs. Among a
population of pneumonia cases in which a virus was detected in
the NP/OP, there was likely a mixture of those in whom the virus
had a causal role in pneumonia and those in whom it did not.
The inability to identify which children had pneumonia due to
which virus hampered the study’s ability to determine if higher
viral loads in the NP/OP were associated with pneumonia.
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Besides the lack of a gold standard, other limitations might
have affected our results. First, specimens were taken at one
point in time on admission to the hospital. We observed that
viral load varied with the time since illness onset, with higher
viral load earlier in the course of symptomatic illness for some
viruses. Taking sequential samples in which we could compare
the peak viral load between cases of different clinical severity
would have been optimal. Second, our design precluded us
from assessing the role of viral load in the lung. Upper respiratory tract viral load might reflect the amount of replication in
the local epithelial cells rather than the viral burden in the lung
parenchyma. Evaluation of viral load of specimens from the
lung, either through lung aspirates or bronchoalveolar lavage,
would provide more direct evidence of the role of viral load in
pneumonia severity.
The widespread use of sensitive PCR assays for testing NP/
OP specimens has led to a higher reported prevalence of pneumonias attributed to respiratory viruses in both adults and
children [2]. Due to the high prevalence of viral infections of
the URT itself, however, it is difficult to conclude that detection
of a virus in the URT of a pneumonia patient is equivalent to
having pneumonia due to that virus. In the PERCH study, the
viral loads in the NP/OP of pneumonia patients are unlikely
to further clarify the role of that virus in causing pneumonia.
However, the PERCH study design was not optimal to answer
this question definitively. Further research, such as longitudinal studies and animal models, is needed to better elucidate the
interpretation of viral load in the diagnosis and clinical management of viral pneumonia.
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